Quest Offers Consumer-Initiated Alzheimer Disease Risk Assessment Blood Test
A blood-based biomarker test has been made available to help individuals identify their risk of developing Alzheimer disease.
Stay updated with breaking news from Detect Amyloid Beta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A blood-based biomarker test has been made available to help individuals identify their risk of developing Alzheimer disease.
A blood-based biomarker test that assesses beta amyloid protein has been made available by Quest Diagnostics to help individuals identify their risk of developing Alzheimer disease.
Medical laboratories company Quest Diagnostics has made a blood test assessing biomarkers of Alzheimer's disease commercially available to consumers in the United States.
A blood-based biomarker test that assesses beta amyloid protein has been made available by Quest Diagnostics to help individuals identify their risk of developing Alzheimer disease.
The test from Quest Diagnostics looks at a certain brain protein is known to contribute to the condition.